Additionally, pramlintide monotherapy only has a modest effect on body weight loss compared to for example glucagon-like peptide 1 (GLP-1) receptor agonists ( via novel unimolecular dual agonists, but first we briefly consider results from studies with other amylin-based agents
Avoidance of hypoglycemia is also a potential consideration for switching treatments, but there are no head-to-head data indicating any advantage of one GLP-1 receptor agonist over any other in terms of the incidence of hypoglycemia
To further characterize protein expression, we employed western blotting to assess the protein levels of ADRB2, BCL3, EGR1, FOS, and MAP3K8 in the liver tissues of rats from different groups (Fig
These can include nausea, bloating, or mild gastrointestinal discomfort, which are common and typically subside after a few days